Predicting Biochemical Recurrence-Free Survival for Patients With Positive Pelvic Lymph Nodes at Radical Prostatectomy
- 31 July 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 184 (1), 143-148
- https://doi.org/10.1016/j.juro.2010.03.039
Abstract
Purpose: We evaluated predictors of freedom from biochemical recurrence in patients with pelvic lymph node metastasis at radical prostatectomy. Materials and Methods: Of 207 patients with lymph node metastasis treated with radical prostatectomy and bilateral pelvic lymph node dissection 45 received adjuvant androgen deprivation therapy and 162 did not. Cox proportional hazards regression models were used to investigate predictors of biochemical recurrence after radical prostatectomy. Recurrence probability was estimated using the Kaplan-Meier method. Results: A median of 13 lymph nodes were removed. Of the patients 122 had 1, 44 had 2 and 41 had 3 or greater positive lymph nodes. Of patients without androgen deprivation therapy 103 had 1, 35 had 2 and 24 had 3 or greater positive lymph nodes while 69 experienced biochemical recurrence. Median time to recurrence in patients with 1, 2 and 3 or greater lymph nodes was 59, 13 and 3 months, respectively. Only specimen Gleason score and the number of positive lymph nodes were independent predictors of biochemical recurrence. Recurrence-free probability 2 years after prostatectomy in men without androgen deprivation with 1 positive lymph node and a prostatectomy Gleason score of 7 or less was 79% vs 29% in those with Gleason score 8 or greater and 2 or more positive lymph nodes. Conclusions: Prognosis in patients with lymph node metastasis depends on the number of positive lymph nodes and primary tumor Gleason grade. Of all patients with lymph node metastasis 80% had 1 or 2 positive nodes. A large subset of those patients had a favorable prognosis. Full bilateral pelvic lymph node dissection should be done in patients with intermediate and high risk cancer to identify those likely to benefit from metastatic node removal.Keywords
This publication has 24 references indexed in Scilit:
- Pretreatment Prostate-Specific Antigen (PSA) Velocity and Doubling Time Are Associated With Outcome but Neither Improves Prediction of Outcome Beyond Pretreatment PSA Alone in Patients Treated With Radical ProstatectomyJournal of Clinical Oncology, 2009
- Indications, Extent, and Benefits of Pelvic Lymph Node Dissection for Patients with Bladder and Prostate CancerThe Oncologist, 2009
- Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastasesThe Prostate, 2008
- Is Pelvic Lymph Node Dissection Necessary in Patients with a Serum PSA<10ng/ml Undergoing Radical Prostatectomy for Prostate Cancer?European Urology, 2006
- Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of <=10 ng/mL and biopsy Gleason score of <=6, and their influence on PSA progression-free survival after radical prostatectomyBJU International, 2006
- The Association Between Total and Positive Lymph Node Counts, and Disease Progression in Clinically Localized Prostate CancerJournal of Urology, 2006
- Disease Progression and Survival of Patients With Positive Lymph Nodes After Radical Prostatectomy. Is there a Chance of Cure?Journal of Urology, 2003
- Is a Limited Lymph Node Dissection An Adequate Staging Procedure for Prostate Cancer?Journal of Urology, 2002
- Extended Pelvic Lymphadenectomy In Patients Undergoing Radical Prostatectomy: High Incidence Of Lymph Node MetastasisJournal of Urology, 2002
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerThe New England Journal of Medicine, 1999